Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology has filed a registration statement for a proposed underwritten public offering of 6,200,000 shares of its common stock. Additionally, the underwriters may purchase up to 930,000 more shares. The offering price is yet to be determined, and is subject to market conditions. Goldman Sachs, BofA Securities, Cowen, and Barclays are the joint book-running managers for this offering. The company aims to utilize the proceeds to enhance its clinical-stage immunology initiatives targeting infectious diseases, including SARS-CoV-2 and hepatitis B.
- Proposed offering of 6,200,000 shares could strengthen financial position.
- Additional option for underwriters to purchase 930,000 shares may bolster funding.
- Pending SEC approval of the registration statement may delay the offering.
- Potential dilution of shares could negatively impact existing shareholders.
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 6,200,000 shares of its common stock. In addition, Vir expects to grant the underwriters a 30-day option to purchase up to 930,000 additional shares of its common stock offered at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, BofA Securities, Cowen and Barclays are acting as joint book-running managers for the proposed offering. Needham & Company is acting as lead-manager for the proposed offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at PostSaleManualRequests@broadridge.com, or by telephone at (833) 297-2926; and Barclays Capital Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “candidate,” “continuing,” “developing” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding, among other things, the timing, size and completion of the proposed public offering. Many factors may cause differences between current expectations and actual results in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities. These and other risks and uncertainties are described in Vir’s filings with the SEC, including in the risk factors included in Exhibit 99.2 to its Current Report on Form 8-K filed with the SEC on July 6, 2020. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
FAQ
What is the size of the proposed offering by Vir Biotechnology (VIR)?
Who are the underwriters for Vir Biotechnology's stock offering?
Will there be any additional shares offered in the Vir Biotechnology public offering?
What is the purpose of the proposed stock offering for Vir Biotechnology?
What risks are associated with Vir Biotechnology's public offering?
